Warby Parker (WRBY) Liabilities and Shareholders Equity (2020 - 2026)
Warby Parker's (WRBY) quarterly Liabilities and Shareholders Equity came in at $736.4 million in Q1 2026, up 7.86% YoY from $682.8 million in Q1 2025, and up 2.15% on a QoQ basis from $720.9 million in Q4 2025.
Warby Parker (WRBY) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Warby Parker (WRBY) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $736.4 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 7.86% year-over-year to $736.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.9 billion (up 9.59% YoY) and the FY2025 annual result came in at $720.9 million, up 6.57% from the prior year.
- Liabilities and Shareholders Equity improved to $736.4 million in Q1 2026, from $720.9 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $736.4 million in Q1 2026 to a low of $543.6 million in Q2 2022.
- A 5-year average of $621.0 million and a median of $592.9 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity grew 29.06% — and 2023, when it rose 2.04%.
- Tracing WRBY's Liabilities and Shareholders Equity over 5 years: stood at $568.7 million in 2022, then climbed by 2.04% to $580.3 million in 2023, then climbed by 16.57% to $676.5 million in 2024, then grew by 6.57% to $720.9 million in 2025, then rose by 2.15% to $736.4 million in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $736.4 million (Q1 2026), $720.9 million (Q4 2025), and $706.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 20.88 Bn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 50.73 Bn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | 31.10 Bn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 8.97 Bn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 39.35 Bn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 4.08 Bn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 14.24 Bn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | 12.48 Bn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 19.79 Bn |
| 10 | Warby Parker | 3.41 Bn | 3.12 Bn | 136.46 Mn | 772.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 772.32 Mn |
| Mar 31, 2026 | 736.41 Mn |
| Dec 31, 2025 | 720.92 Mn |
| Sep 30, 2025 | 706.92 Mn |
| Jun 30, 2025 | 701.90 Mn |
| Mar 31, 2025 | 682.76 Mn |
| Dec 31, 2024 | 676.49 Mn |
| Sep 30, 2024 | 637.99 Mn |
| Jun 30, 2024 | 618.21 Mn |
| Mar 31, 2024 | 592.89 Mn |
| Dec 31, 2023 | 580.31 Mn |
| Sep 30, 2023 | 574.88 Mn |
| Jun 30, 2023 | 561.71 Mn |
| Mar 31, 2023 | 557.88 Mn |
| Dec 31, 2022 | 568.71 Mn |
| Sep 30, 2022 | 550.15 Mn |
| Jun 30, 2022 | 543.56 Mn |
| Mar 31, 2022 | 544.67 Mn |
| Dec 31, 2021 | 440.65 Mn |
| Sep 30, 2021 | 459.56 Mn |